Mast Group says its MRSA test will reduce lab time

Mast Group has recommended its GenoType MRSA test because it is able to reduce laboratory turnaround time.

According to the company, the product can detect markers for S.epidermidis, MecA, S.aureus and Panton-Valentine Leukocidin (PVL) on one strip.

It cited a recent Lancet article that discussed the risks of community-acquired MRSA and the possibility of PVL infections and outbreak strains.

"The escalation of morbidity and mortality associated with PVL infections has attracted wide spread media attention," Mast Group said in a statement.

It added that most UK labs cannot confirm PVL presence and therefore have to outsource presumptive isolates – therefore Mast Group’s test is useful for speeding up the process.

The company’s announcement follows its news last month about a PCR assay that could help to detect up to 12 pathogens, some of which cover H1N1 influenza.

It highlighted the Seeplex range, which uses patented Dual Priming Oligonucleotide technology and is said to offer sensitivity and specificity.